NanoRepro AG
NNGRF
Other OTC12.76
USD
- -
- -
ISIN
DE0006577109
Return %
Stock
S&P500
1Y
- -
18.21
3Y
- -
64.38
5Y
- -
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lisa Jungst
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Untergasse 8 Marburg Germany 35037
- IPO Date
- Mar 2, 2021
- Website
- nanorepro.com
- Similar Companies
- Business
- NanoRepro AG develops, manufactures and distributes CE-certified rapid diagnostic tests and food supplements for home and professional use in Germany and internationally; its core products include self-tests for family planning, preventive healthcare, food intolerances, allergies and infectious diseases such as AIDS, Troponin I, D-dimer, streptococci antigen, influenza A/B, microalbumin, SARS-CoV-2 antibodies and corona antigens; hospital and practice tests; immunochromatographic lateral flow tests for biomarkers; and Alphabiol branded food supplements like Beauty Elixier for skin health, Fertility for men and Curcumin Elixier with Vitamin D. The company, founded in 2006 and headquartered in Marburg, Germany, operates in the biotechnology and diagnostics sector with approximately 20 employees and trades on the Frankfurt Stock Exchange under ticker NN6 (OTC: NNGRF). In 2024, NanoRepro achieved 76% revenue growth to 4.4 million euros driven by self-tests (up 60% to 3.7 million euros) and food supplements (up 180% to 650,000 euros), bolstered by partnerships with dm (eight tests under Mivolis brand) and Lidl Austria (ZuhauseTEST displays); it acquired a 50.03% majority stake in PaediProtect AG (2024 revenue 11.5 million euros, specializing in child/baby skincare) in August 2024, holds 10% direct and 22.4% indirect in Deutsche Kosmetikwerke AG (2024 revenue up 74% to 1.65 million euros, focused on skincare), expanded its Viromed partnership for real-time PCR instruments, received EU IVDR quality certification in April 2025 and invested in cold plasma technology to strengthen its health and lifestyle market position.